Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Clinical Pharmacology Année : 2020

Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions

Résumé

Purpose: Drug-drug interactions (DDIs) require monitoring in an aging population with increasing polypharmacy exposure. We aimed to estimate the prevalence of exposure to potential DDIs using the French healthcare insurance system database, for six DDIs with various clinical relevance: angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs (ARBs-ACEIs + NSAIDs), antiplatelet agents and NSAIDs (AAP + NSAIDs), serotonergic drugs and tramadol (SD + T), statins and macrolides (S + M), oral anticoagulant and NSAIDs (OAC + NSAIDs), and colchicine and macrolides (C + M). Methods: We used exhaustive healthcare data from a 1/97th random sample of the population covered by the French health insurance system (EGB) between 2006 and 2016. Exposure to a DDI was defined as overlapping exposure to two interacting drugs. The prevalence of exposure was estimated by year. Results: Prevalence of exposure in 2016 was estimated at 3.7% for ARBs-ACEIs + NSAIDs, 1.5% for AAP + NSAIDs, 0.76% for SD + T, 0.36% for S + M, 0.24% for AOC + NSAIDs, and 0.02% for C + M. In 26% to 58% of episodes of exposure, the two interacting drugs were prescribed by the same physician and dispensed by the same pharmacy the same day. Between 2006 and 2016, the yearly prevalence was increasing for SD + T and for DDIs involving NSAIDs, and it was decreasing for those involving macrolides. Conclusion: Exposures to potential DDIs in France are not uncommon with a high proportion resulting from a co-prescription by the same physician. Monitoring the prevalence of exposure to DDIs is needed to implement prevention measures. Administrative data enable this surveillance in large and representative cohorts.
Fichier principal
Vignette du fichier
CSouty_2020_HAL.pdf (736.89 Ko) Télécharger le fichier
CSouty_2020_HAL_Appendix.pdf (414.29 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02946690 , version 1 (23-09-2020)

Identifiants

Citer

Cécile Souty, Titouan Launay, Olivier Steichen, Cécile Conte, Clément Turbelin, et al.. Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. European Journal of Clinical Pharmacology, 2020, ⟨10.1007/s00228-020-02952-7⟩. ⟨hal-02946690⟩
172 Consultations
236 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More